ASP3082
setidegrasib
PHASE1
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Peak Sales Est$1500M
Mechanism: KRAS G12D degrader
Expert: Selective protein degrader targeting KRAS G12D mutation.
Everyday: Destroys a mutant protein that drives pancreatic cancer.
Targets: ["KRAS"]
Programs (1)
Upcoming Catalysts (2)
ASP3082 (Setidegrasib) - Pancreatic Cancer - Ph3 - Start
By Mar 2026
ASP3082 - NSCLC - Registrational Study Preparation
2026
Notes
First-in-class KRAS G12D degrader. In-house discovery. Potential in pancreatic cancer.
Data from Supabase · Updated 2026-03-24